


Outline PET imaging PET based BGRT Stanford IDE study RefleXion system overview RefleXion X1 commissioning and QA



Biological Imaging in Radiation Therapy

- CT and MRI improved structure visualization with enhanced sptial resolution.
- PET imaging visualize biological and molecular level in tumor
- Wide spectrum of positron-emitting tracer to cover more disease sites with high sensitivity


			SPAT	TAL RESOLUT	non	
		10µm	100yam	1000	10mm	
ATT .	=-	MICROSCOPY	TCAL MACROSCOPIC	SP USPECT	PET	RECEPTORS
MOLECULAR SENSITIVITY	1-		HIGH FIEL	MRI	MRS	ENZYMES
MOLE	1-		¥-RAY	FULL BO	~)~	STRUCTURES
		L				
		CELLS	GLANDS/VESSE	1.8	ORGAN STRUCT	URE
		Figure a	dapted from Ticher, H	L, et al. Phys. M	ed. Biol. 60 (2015) I	R208-R289
						(1)

4

Why PET-based BGRT?

٩


- Oligometastatic disease -- 3 to 5 or fewer metastases
- Clinical trial of 3 sited and 5 sited NSCLC shows the improved overall survival (6-24 months). (Gomez 2019 JCO, Iyengar JAMA 2018)
- Biologically tracking the oligometastases: Redefining the role for radiotherapy in metastatic cancer.
- PET imaging reveals tumor characteristics of tumors and biological response to treatment: perfect tools BGRT




BGRT Planning Studies


- Lung BGRT studies by City of Hope: (Liang et al, ASTRO 2019)
 Clung SDPT activate
- 6 lung SBRT patients.
 BGRT vs ITV-based SBRT, PTV volume reduced 21.5% in average.
- OAR sparing is better for the lungs, spinal cord, esophagus, and heart
- Emory's study to investiage stability of FDG F18 as a "fiducial" for SBRT (Tian et al, ASTRO 2019)
 - 14 lung SBRT patients, 10Gy x 5fx
- 3 PET/CTs acquired before the 1, 2, and 5th fx.
 mean SUVmax change from PET1-2 = -8.2%, from PET1-3 = -7.0%.
- [SUVmax/liver SUVmean] was stable over time; PET1-2=-0.3%, PET1-3 = +1.8%.
- Reflexion set SUVmax/SUVmean in BTZ threshold is 2.7 for simulation, 2.0 for treatment tracking.

7



8







Stanford IDE Study


Primary Objectives:

- To identify the Recommended RefleXion FDG Dose (RRFD) that enables the use of biology-guided radiotherapy (BgRT) on the RefleXion system. (Cohort I: RRFD)
 To determine whether BgRT dose distributions generated from Limited Time Sample (LTS)
- Positron Emission Tomography (PET) images obtained at the time of treatment delivery are consistent with the approved BgRT plan. (Cohort II: Emulated Delivery)
- Design
 - Cohort I RRFD: 6 to 12 subjects (3 to 6 bone tumors, 3 to 6 lung tumors)
- Cohort II Emulated Delivery: 8 to 12 subjects (4 or more bone tumors, 4 or more lung tumors)
 Primary End Point: Cohort I: Recommended Reflexion FDG Dose (RRFD): The FDG dose that results in Activity
 - Concentration necessary for BgRT functioning. (5t B/g) in the Document ratio in rearry Concentration necessary for BgRT functioning. (5t B/g) in the provide the result of the second state of the se



































































			FWHM) betw width <0.5m		asure and TPS	8 modeled
-	Y-jaw (mm)	Field size X (mm)	Depth (mm)	TPS FWHM (mm)	Measured FWHM (mm)	
			15.0	20.0	20.0	
		1	50.0	21.1	20.9	1
	20mm	400.0	100.0	22.7	22.0	
			150.0	23.8	23.4	
			200.0	25.0	24.6	
			15.0	10.0	9.9	
			50.0	10.5	10.4	
	10mm	400.0	100.0	11.1	11.0	1
			150.0	11.9	11.7	
			200.0	12.5	12.3	

-	


ommissioning Plan				- Station
Assivatric Tests	(Janux MLC)	Death	550	Conveleter
Dose Profiles/PDDs in Water Phantom	And a start of the			
7.1 PDOs	(1 x 0.625, 1.25, 2.5, 5, 10, 20, 40); (2 x 0.625, 1.25, 2.5, 5, 10, 20, 40)		85	2 Fait
7.2 Profiles	11 x 0.625, 1.25, 2.5, 5, 10, 20, 401 (2 x 0.625, 1.25, 2.5, 5, 10, 20, 40)	1.5, 5, 10, 15, 20	85	E Pass
7.3 PDDs	1 x 5, 10, 20, 401: (2 x 5, 10, 20, 40)		70	2 7am
7.4 Profiles	(1 × 5, 10, 20, 40); (2 × 5, 10, 20, 40)	1.5	70	E Pass
8.1 Output factors	[1 × 0.625, 1.25, 2.5, 3.75, 5, 7.5, 10, 15, 20, 30, 40]; [2 × 0.625, 1.25, 2.5, 3.75, 5, 7.5, 10, 15, 20, 30, 40]	50	85	E Pass
8.2 Reference calibration condition check	[2, 50]; 85 SSD	1.5	85	E Pass
8.3 70 cm 550	[2, 30]: 70 SSD	1.5	70	E Pass
9.1 Gentry 0, various field sizes	(1 × 1.25, 2.5, 5, 10, 20, 40); (2 × 1.25, 2.5, 5, 10, 20, 40)		85cm SAD	E Pass
9.2 TG-244 plans (Abdomen, Thorax, Lung, HN, Prostate, Anal)				C Pass
9.3 TG-119 Prostate, HN, Cshape, Brain met 1.5, 2 and 3cm				E 7ass
9.4 3 HN plans				C Pass
9.5 3 prostate plans				2 Pass
9.6 3 long plans				E Pass
9.7 3 SBRT lung				E Pass
Solid water phantom				
10.1 TG119 INRT Prostate				🖾 Pass
10.2 TG119 IMRT HN				E Pass
10.3 TG119 C shape easy and hard				C Pass
10.4 Brain met 1.5cm				E 7411
10.5 Brain met 2on				C Pass
10.6 Brain met 3cm				2 Pass
Solid water phantom with heterogeneous slabs				
11.1 Lung and bone				2 Pass
Motion management/heterogeneity - Lung Phantom				
12.1 Single target lung ITV-based plan - static				🖾 Patt
12.2 Single target lung ITV-based plan - with motion				E Pass
Off-Asis Targets				
13.1 Brain E2E in CK Head phantom				E Pass
13.2 SBRT Mets in solid water phantom				2 Mars
Seam Interruption (E-2-E)				- L 3
14.1 Plan interrupted				
Couch transmission				N




 Tomodose diode array was mounted to the gantry head perpendicular to the beam axis. Set field size to 40cm x 2cm and take measurement at the gantry positions of 0°, 90°, 180° and 270°. The dose and symmetry vs. gantry angle variation <2%. 							
B 14 4	Dose %	Symmetry X %	Symmetry Y %				
Deviation to average Gantry 0	0.113	0.2	0.44				
	0.113 0.213	0.2	0.44				
Gantry 0				And A			
Gantry 0 Gantry 90	0.213	0.13	0.27				



32





33

$k_{Qmsr,Q_0}^{\mathit{fmsr,fref}}$

 $k_{Q_{our},Q_{c}}^{f_{our},f_{our}} = \frac{\left(D_{w}^{f_{our}}/D_{det}^{f_{our}}\right)_{6MV FFF,SSD=85 cm,FS=10 \times 3 cm^{3} z=10 cm}}{\left(D_{w,Q}^{f_{our}}/D_{det}^{f_{our}}\right)_{Ca^{60},SSD=100 cm},FS=10 \times 10 cm^{3} z=5 cm}$


Absolute Beam Calibration


Exradin A14 ion chamber: Collecting Volume 0.015 cm3 Collector Diameter 0.3 mm Collector Diameter 0.3 mm

- MSR field: 10x 3cm²:
- Reference Clinical Field A: 10 x 2cm².
- Calibrate machine output to 1cGy/MU for Clinical Field at Nominal dmax = 1.5cm.
- Considering PDD=0.575, and OF= 0.952

 Dcal @ At 10cm Depth of MSR field expected value 0.6044cGy/MU.

34





kVCT Tube Votage, Current and Imaging Dose


- RTI MAS-2 and Piranha are used to verify the mA and voltage
- The CTDI phantom was set up with a Standard Imaging A101 pencil chamber with a protocol of 120kVp, 150mAs and 1.25mm slice thickness.
- The voltage and current are within 5% of the setting of 120 kV and 150 mA.
- CTDI100(center) = 3cGy.
- CTDI periphery =3.6cGy.
- The CTDIw = **1.4cGy** (body) and **3cGy** (head)

37











Summary

- Reviewed PET imaging and PET based BGRT
- Introduced Stanford IDE study
- Overviewed RefleXion X1 system
- Presented reults of RefleXion X1's commissioning and QA

